Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > NASDAQ

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 24, 2021 11:05am

115 Views

Post# 32866189

RE:RE:RE:RE:RE:RE:NASDAQ

WalkOverTheStrt wrote: Arbourmark - sure thing
1 - Listing won't get the stock to $6 instantly, never implied that as my point was there aren't enough potential buyers (esp. instiutions) to purchase. Look at the liquidity of this stock. It's anemic. It's about liquidity and lack of any on this stock / exchange. I've been buying for the last two years (relaievly new investor) and medium to large blocks are difficult to buy into. That and fact that majority of shares (outside of owners %) is held by retail tell's me whatever PR / news of the last year since hiring Stern isn't working and / or it can't be acted on b/c we are on this exchange. If you represent a fund and Stern / Antibe comes calling are you going to take their call... maybe but if you cannot buy due to the exchange then it's a put on the shelve situation. We have a great

2. Agree that there are shorts and right now they have free reign as there are no buy side instiutions adding. Again my hypo is there just aren't enough out there on this exchange that cover biotech / micro caps...

3.. The Min price on NASDAQ is $3. We qualify now and I'd expect mgmt to list when they are close to signing a European or USA partner... If that isn't enough for the market to see the value prop of Antibe (after already having sifficient cash on hand, large TAM) then I'm not sure what will do it... This we need to be at $x is bs IMO. It's about following the listing with news that get's attention and performing roadshows to attract the target instiutions.
https://listingcenter.nasdaq.com/assets/initialguide.pdf

Sorry, I didn't mean to imply that the company is waiting for a certain price before they go to NASDAQ. I just know I like a certain price range and I believe we will be there when we finally go (likely fall - based on latest comments from ATE).

I am saying that I believe, by the time we go, the share price will likely be between $6 and $15.
My opinion only. I like that range (with lots of good news to follow - key requirement) as it would set us up nicely so we can focus on developing the company and not worrying about a declining share price.

I'm sticking with that guess - as it is only a guess.

Just my opinion

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?